

**PERSONAL INFORMATION** **Joaquin Mateo****WORK EXPERIENCE**

November 2017–Present

**Group Leader**

Vall d'Hebron Institute of Oncology (Spain)

- Team Leader, Prostate Cancer Translational Research Group, Vall d'Hebron Institute of Oncology.
- Medical Oncologist; GU Cancers Division, Vall d'Hebron University Hospital, Barcelona.

June 2013–November 2017

**Clinical Research Fellow**

The Institute of Cancer Research (United Kingdom)

September 2011–June 2013

**Clinical Fellow**

The Royal Marsden NHS Trust (United Kingdom)

May 2011–September 2011

**Locum Consultant**

Catalan Institute of Oncology (Spain)

May 2007–May 2011

**Doctor in Training**

Bellvitge University Hospital (Spain)

**EDUCATION AND TRAINING**

2014–2017

**PhD**

University of London - The Institute of Cancer Research (United Kingdom)

PhD in Cancer Genomics

–2011

**MSc**

Universitat de Barcelona (Spain)

Master Degree in Health Sciences (MSc)

2010–2011

**Postgraduate studies**

Universitat de Barcelona (Spain)

Postgraduate studies: Clinical Trial Design

2007–2011

**Specialist in Medical Oncology**

Spanish Ministry of Health (Spain)

Board Certification - Medical Oncology

2000–2006

**MD**

Universitat de Barcelona (Spain)

Degree in Medicine (MD)

**ADDITIONAL INFORMATION****Expertise**

- Early drug development

- Prostate cancer
- Clinical Trials
- Biomarker development
- Cancer Genomics

**Publications**

H Index = 22 (Updated 20/11/19, Scopus)

Total Number Publications D1: 38 (16 D1 publications as lead or joint lead author; 2 as corresponding author D1)

Total Number Publications Q1: 42

Total Number Publications as lead author: 23

Total number of publications as corresponding author: 4

**PUBLICATIONS**

- 1 -. Scientific paper. Joaquin Mateo; et al. (23/1). 2018. Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. *Eur Urol. Elsevier*. pp. doi: 10.1016/j.eururo.2018.01.010.
- 2 -. Scientific paper. Joaquin Mateo; et al. (41/1). 2019. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised phase 2 trial. *Lancet Oncology*. ePub ahead of print-Nov 2019.
- 3 -. Scientific paper. Sharp, Adam; et al. (35/1). 2019. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. *EUROPEAN UROLOGY. ELSEVIER*. 76-5, pp.676-685. ISSN 0302-2838.
- 4 -. Scientific paper. Mateo, Joaquin; Carreira, Suzanne; de Bono, Johann S.(3/1). 2019. PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers. *EUROPEAN UROLOGY. ELSEVIER*. 76-4, pp.459-460. ISSN 0302-2838.
- 5 -. Scientific paper. Abida, Wassim; et al. (43/24). 2019. Genomic correlates of clinical outcome in advanced prostate cancer. *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. NATL ACAD SCIENCES*. 116-23, pp.11428-11436. ISSN 0027-8424.
- 6 -. Scientific paper. Athie, Alejandro; et al. (9/9). 2019. Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer. *CURRENT ONCOLOGY REPORTS. SPRINGER*. 21-5. ISSN 1523-3790.
- 7 -. Scientific paper. Zafeiris Zafeiriou; et al. (21/16). 2019. Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. *European Urology. Elsevier*. 75-1, pp.184-192 doi: 10.1016/j.eururo.2018.09.048.
- 8 -. Scientific paper. Rodrigues, Daniel Nava; et al. (52/8). 2018. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer (vol 128, pg 4441, 2018). *JOURNAL OF CLINICAL INVESTIGATION. AMER SOC CLINICAL INVESTIGATION INC*. 128-11, pp.5185-5185 doi: 10.1172/JCI125184.
- 9 -. Scientific paper. Mateo, J.; et al. (15/1). 2018. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). *Ann Oncol. OXFORD UNIV PRESS*. 29-9, pp.1895-1902 doi: 10.1093/annonc/mdy263.
- 10 -. Scientific paper. Seed, George; et al. (21/3). 2017. Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. *CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH*. 23-20, pp.6070-6077 doi: 10.1158/1078-0432.CCR-17-0972.
- 11 -. Scientific paper. Mateo, Joaquin; et al. (23/1). 2017. A First-Time-in-Human

- Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors Clin Cancer Res. AMER ASSOC CANCER RESEARCH. 23-19, pp.5981-5992 doi: 10.1158/1078-0432.CCR-17-0725.
- 12 -. Scientific paper. Goodall, J Mateo, J (joint first author); et al. (34/2). 2017. Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition Cancer Discov. AMER ASSOC CANCER RESEARCH. 7-9, pp.1006-1017 doi: 10.1158/2159-8290.CD-17-0261.
- 13 -. Scientific paper. Perez-Lopez, Raquel; et al. (19/2). 2017. Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study RADIOLOGY. RADIOLOGICAL SOC NORTH AMERICA. 283-1, pp.168-177 doi: 10.1148/radiol.2016160646.
- 14 -. Scientific paper. Massard, C.; et al. (14/2). 2017. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone ANNALS OF ONCOLOGY. OXFORD UNIV PRESS. 28-1, pp.90-95 doi: 10.1093/annonc/mdw441.
- 15 -. Scientific paper. Pritchard, C. Mateo, J (joint first author); et al. (42/2). 2016. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer New Engl J Med. MASSACHUSETTS MEDICAL SOC. 375-5, pp.443-453 doi: 10.1056/NEJMoa1603144.
- 16 -. Scientific paper. Perez-Lopez, Raquel; et al. (12/5). 2016. Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer RADIOLOGY. RADIOLOGICAL SOC NORTH AMERICA. 280-1, pp.151-160.
- 17 -. Scientific paper. Mateo, J.; et al. (18/1). 2016. An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib TARGETED ONCOLOGY. SPRINGER. 11-3, pp.401-415 doi: 10.1007/s11523-016-0435-8.
- 18 -. Scientific paper. Mateo, Joaquin; et al. (14/1). 2016. A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies BRITISH JOURNAL OF CANCER. NATURE PUBLISHING GROUP. 114-8, pp.889-896 doi: 10.1038/bjc.2016.59.
- 19 -. Scientific paper. Mateo, J.; et al. (51/1). 2015. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer New Engl J Med. MASSACHUSETTS MEDICAL SOC. 373-18, pp.1697-1708 doi:10.1056/NEJMoa1506859.
- 20 -. Scientific paper. Frenel, Jean Sebastien; et al. (23/16). 2015. Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. 21-20, pp.4586-4596 doi: 10.1158/1078-0432.CCR-15-0584.
- 21 -. Scientific paper. Robinson, Dan; et al. (73/53). 2015. Integrative Clinical Genomics of Advanced Prostate Cancer CELL. CELL PRESS. 161-5, pp.1215-1228 doi: 10.1016/j.cell.2015.06.053.
- 22 -. Review. Joaquin Mateo; Suzanne Carriera; Johann de Bono. (3/1). 2019. PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers Eur Urol. ELSEVIER. ePub ahead of print, pp.doi: 10.1016/j.eururo.2019.03.029.
- 23 -. Review. Joaquin Mateo; Joan Carles. (2/1). 2018. Towards a New Classification for Metastatic Prostate Cancer Eur Urol. pp. doi: 10.1016/j.eururo.2018.10.058.
- 24 -. Mateo, J.; Carreira, S.; de Bono, J. S.2017. Acquiring evidence for precision prostate cancer care ANNALS OF ONCOLOGY. 28-5, pp.916-917 doi: 10.1093/annonc/mdx105.
- 25 -. Mateo, Joaquin; et al. (10/1). 2017. DNA Repair in Prostate Cancer: Biology and Clinical

Implications EUROPEAN UROLOGY. 71-3, pp.417-425

doi: 10.1016/j.eururo.2016.08.037. Epub 2016 A.

26 -. Lorente, David; et al. (5/2). 2015. Sequencing of agents in castration-resistant prostate cancer LANCET ONCOLOGY. 16-6, pp.E279-E292

doi: 10.1016/S1470-2045(15)700.

27 -. Alejandro Athie; et al. 2019. Targeting DNA repair defects for precision medicine in prostate cancer Curr Oncol Rep. 21-5, pp.42

doi: 10.1007/s11912-019-0790-6.

#### Projects Participation in R&D and Innovation projects.

1 -. P-FIS 2019: Biomarkers based on DNA repair defects for prostate cancer stratification Instituto de Salud Carlos III. Sara Arce. (Vall Hebron Institute of Oncology). 01/01/2020-31/12/2024. 82.400 €. Co-ordinator.

2 -. PERIS FELLOWSHIP 2019: Combined analysis of liquid biopsies to monitor tumor evolution and anticancer therapy response Health Department; Generalitat de Catalunya. Irene Casanova-Salas. (Vall Hebron Institute of Oncology). 01/10/2019-31/12/2021. 113.284 €. Co-ordinator.

3 -. FIS: Prostate cancer molecular profiles associated with DNA repair defects towards the development of precision medicine strategies. Instituto de Salud Carlos III (FIS Program). (Vall Hebron Institute of Oncology).

01/01/2019-31/12/2021. 209.000 €. Principal investigator.

4 -. Clinical Qualification of DNA Repair Defects as Biomarkers in Metastatic Prostate Cancer Using Integrated Genomics and Tissue-Based Functional Assays Department of Defense, USA Government. Joaquin Mateo. (Vall Hebron Institute of Oncology). 01/10/2018-01/10/2021. 2.122.000 €. Principal investigator.

5 -. Novel approaches to liquid biopsy in prostate cancer to inform precision medicine Fundacion FERO. (Vall Hebron Institute of Oncology). 02/09/2019-01/09/2021. 80.000 €. Principal investigator.

6 -. Co-targeting androgen receptor signalling and DNA damage repair for precision therapy in advanced prostate cancer (AR-DDR) European Commission H2020 Program. (Vall Hebron Institute of Oncology). 01/05/2019-30/07/2021.

172.940 €. Principal investigator.

7 -. Prostate Cancer Foundation Young Investigator Award Prostate Cancer Foundation. Joaquin Mateo Valderrama. (Vall Hebron Institute of Oncology). 01/10/2016-30/09/2019. 225.000 €. Principal investigator.

8 -. Medical Research Council Fellowship Medical Research Council UK.

Joaquin Mateo Valderrama. (The Institute of Cancer Research).

01/09/2014-31/08/2017. 275.000 €. Principal investigator.

9 -. Next generation sequencing for BRCAness from archival tumour samples to identify prostate cancer patients benefiting from treatment with PARP inhibitors (co-investigador, no beneficiario) NHS Biomedical Research Centre. Johann de Bono. (The Institute of Cancer Research). 01/05/2015-30/04/2016. 118.000 €.

#### Memberships

#### Other Relevant Information